Introduction {#Sec1}
============

Wilson's disease (WD, OMIM: 277900), also referred to as hepatolenticular degeneration, is a systemic disorder of copper metabolism with an autosomal recessive mode of inheritance. Hepatic or neurological symptoms are the primary manifestations. The estimated prevalence of WD is 1 in 7000 to 1 in 100,000, and gene carrier frequency is estimated at more than 1 in 90 (Scheinberg and Sternlieb [@CR29]; Olsson et al [@CR24]; Coffey et al [@CR3]). Most patients develop initial symptoms during the second and third decades of life.

The gene responsible for WD is located on chromosome 13, band q14.3 (13q14.3-q21.1). This gene encodes a membrane-bound, copper-transporting P-type ATPase (ATP7B, OMIM: 606882) that is crucial for the excretion of copper by hepatocytes and its binding to ceruloplasmin. Thus far, approximately 500 mutations of APT7B have been identified. No direct genotype-phenotype correlation has been proven regarding WD, as the data published to date have shown somewhat conflicting results (Houwen et al [@CR16]; Ha-Hao et al [@CR15]; Stapelbroek et al [@CR33]; Vrabelova et al [@CR35]; Gromadzka et al [@CR11]). However, one consistent finding suggests that patients with severe mutations (e.g., frameshift and nonsense mutations) present earlier onset of the disease and more severe metabolic disturbances than patients with missense mutations (Gromadzka et al [@CR10]). It is also clear that patients with the same mutations can display different phenotypes (Deguti et al [@CR7]; Gupta et al [@CR13]). Therefore, it seems reasonable to assume that other compound genetic interactions (other than APT7B mutation), as well as epigenetic and environmental factors, may play an important role in disease presentation (Deguti et al [@CR7]; Das and Ray [@CR6]; Gupta et al [@CR13]; Behari and Pardasani [@CR1]; Litwin and Członkowska [@CR18]).

To capture more precisely the influence of such factors, it is reasonable to compare the clinical presentation of WD among siblings from the same families, rather than in an unrelated patient cohort (Santhosh et al [@CR28]). Data from published familial studies has been somewhat limited and based on small numbers of cases, with inconsistent results (Takeshita et al [@CR34]; Vrabelova et al [@CR35]; Santhosh et al [@CR28]). It appears that even monozygotic twins can display completely different symptom patterns and ages of onset (Członkowska et al [@CR5]).

The aim of the present study was to evaluate the concordance rate and compare the initial clinical and biochemical manifestations of WD among 168 siblings from 73 separate families.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

After obtaining approval from the bioethical committee, index cases (ICs) and their siblings with a confirmed diagnosis of WD and full clinical information (described below) were identified from our registry of 609 patients. All of them underwent clinical investigation and received a diagnosis of WD at the Institute of Psychiatry and Neurology in Warsaw. Diagnosis was based on clinical features, the presence of Kayser-Fleischer rings, serum ceruloplasmin and copper levels, and 24-h urine copper concentration. In most cases, DNA analysis was performed and APT7B mutations were identified according to the method described below.

The following data were included in the analysis:age at symptoms onset (first clinical signs strongly suggestive of WD in symptomatic patients)clinical signs at onset: hepatic or neurologicalage at diagnosisbiochemical parameters at diagnosis, including serum ceruloplasmin, serum copper, and copper concentration in a 24-h urine samplemutation status of the carrier

All ICs were divided into two main groups based on their initial predominant symptoms of WD (i.e., hepatic or neurological) according to the phenotypic classification of Wilson's disease proposed by Ferenci et al in [@CR8]. Siblings were similarly grouped or recognized as presymptomatic (i.e., without signs, symptoms, or laboratory findings suggestive of WD) prior to diagnosis. Hepatic signs and symptoms included abdominal pain, jaundice, ascites, acute/chronic liver failure, hemostatic disturbance, history of hemolytic anemia, and abnormal liver tests. Neurological signs and symptoms included tremor, dystonia, speech, facial expression, gait disturbances, and ataxia, as well as neuropsychiatric disturbances like mood, emotional and behavioral control imbalance, and frank psychosis.

Dividing main groups of patients into subgroups according to the mutation status of the ICs and siblings resulted in patient populations that were too small for genotype-phenotype analysis. Therefore, only basic genetic data was analyzed by subgroup.

Laboratory examinations {#Sec4}
-----------------------

Serum ceruloplasmin levels were measured using the improved colorimetric enzymatic assay developed by Ravin ([@CR27]). Serum copper concentration and 24-h urinary copper excretion were measured using flame atomic absorption spectrometry (FAAS). ATP7B genotyping was performed using polymerase chain reaction restriction fragment length polymorphism analysis and/or direct ATP7B gene sequencing, as described previously (Gromadzka et al [@CR10], [@CR11]).

Statistics {#Sec5}
----------

Variables are reported as means and 95 % confidence intervals (95 % CIs), and were compared between groups using the Mann Whitney U test, analyzed with SPSS Statistics 17.0 software. Values of *p* \< 0.05 were considered statistically significant.

Between-group comparison {#Sec6}
------------------------

To calculate the concordance rate, we employed the proband- or case-wise concordance rate, judging the proportion of individuals with the same trait---here, the first disease manifestation among ICs and their siblings (Smith [@CR32]). The following formula was used in this estimation: Case-wise concordance (Cc) = 2C/(2C + D), where C is the number of concordant siblings and D is the number of discordant pairs (McGue [@CR20]).

Results {#Sec7}
=======

We identified 73 ICs with 95 siblings for analysis. Among ICs, 30 patients (41 %) exhibited predominantly hepatic WD and 43 (59 %) exhibited predominantly neurological WD symptoms at onset.

In the group of 30 ICs with hepatic presentation at onset, there were 21 ICs with 24 siblings that were also symptomatic: 18 (75 %) had hepatic signs and symptoms, six (25 %) had neurological initial manifestation of the disease, and 11 were presymptomatic. Therefore, according to the employed formula (see Methods), there was an 86 % rate of concordance of initial signs and symptoms at onset in this group. We observed no significant differences between hepatic ICs and their respective symptomatic siblings regarding age at onset, age at diagnosis, ceruloplasmin level, serum copper concentration, or 24-h urine copper concentration. We also observed no differences between the hepatic ICs and any of their symptomatic or presymptomatic siblings regarding age at diagnosis, ceruloplasmin and serum copper levels, or 24-h urine copper concentration (Table [1](#Tab1){ref-type="table"}).Table 1Clinical and biochemical characteristics of index cases (ICs) with hepatic signs at onset and their siblingsGroupAll hepatic ICsAll siblings of hepatic ICsHepatic siblingsNeurological siblingsPresymptomatic siblingsN303518611Age at onset, years23.1 (19.7--26.5)NA24.2 (17.8--30.5)25.7 (16.5--34.8)NAAge at diagnosis, years25.2 (21.7--28.6)26.0 (22.3--29.8)27.6 (21.5--30.6)28.7 (19.4--37.9)22.0 (17.1--26.8)Ceruloplasmin, mg/dl11.7 (9.4--14.1)11.5 (9.6--13.4)11.8 (9.1--14.4)7.5 (3.8--11.3)11.5 (7.9--15.1)Serum Cu, μg/dl56.9 (46.8--67.1)51.3 (42.2--60.4)52.0 (39.5--64.4)50.0 (23.8--76.3)50.9 (27.8--74.0)Urinary Cu, μg/24 h181.4 (111.1--251.8)154.7 (88.0--221.5)111.6 (82.6--140.5)105.2 (47.3--257.8)90.0 (58.0--122.0)Data are presented as mean (95 % CI). Laboratory norms: ceruloplasmin: 25--45 mg/dl, serum copper: 70--140 μg/dl, urinary copper: 0--50 μg/24 h*NA* not applicable

In the group of 43 ICs with neurological initial symptoms, we identified 24 ICs with 28 symptomatic siblings: 14 had neurological and 14 had hepatic manifestations at onset. Thirty-two siblings were presymptomatic at the time of diagnosis. This finding constitutes a 66 % concordance rate of initial clinical presentation among neurological ICs and their symptomatic siblings. Although there were no differences between neurological ICs and their symptomatic siblings regarding the age of onset or the age of diagnosis, in this case ICs presented significantly lower ceruloplasmin (*p* = 0.004) and serum copper concentration (*p* = 0.001).

When all neurological ICs were compared with all symptomatic and presymptomatic siblings, we observed no differences regarding age at diagnosis; however, neurological ICs presented significantly lower ceruloplasmin and serum copper concentration levels (Table [2](#Tab2){ref-type="table"}).Table 2Clinical and biochemical characteristics of index cases (ICs) with neurological signs at onset and their siblingsGroupAll neurological ICsAll siblings of neurological ICsHepatic siblingsNeurological siblingsPre-symptomatic siblingsN4360141432Age at onset, years25.3 (23.3--27.2)NA23.7 (17.2--30.2)27.2 (23.1--32.3)NAAge at diagnosis, years26.1 (24.3--27.8)27.2 (24.6--29.9)29.2 (22.6--35.8)28.3 (24.0--32.7)25.9 (21.9--29.9)Ceruloplasmin, mg/dl10.7\* (8.8--12.6)16.8\* (14.8--18.9)17.0 (11.7--22.3)17.6 (12.9--22.2)16.1 (13.4--18.8)Serum Cu, μg/dl32.2\*\* (25.1--39.3)48.8\*\* (43.1--54.3)54.8 (39.6--69.9)50.0 (36.1--64.0)45.3 (38.9--51.8)Urinary Cu, μg/24 h126.6 (96.4--156.8)164.5 (123.5--205.5)126.2 (70.6--181.7)116.8 (77.6--156.0)95.1 (68.4--121.9)Data are presented as mean (95 % CI). Laboratory norms: ceruloplasmin: 25--45 mg/dl, serum copper: 70--140 μg/dl, urinary copper: 0--50 μg/24 h*NA* not applicable\**p* \< 0.001; \*\**p* \< 0.001

Genetic analysis {#Sec8}
----------------

Among hepatic ICs and their symptomatic siblings with analyzed ATP7B mutations, the most frequent mutation was H1069Q (c.3207C\>A), with an allelic frequency of 77 %. In this group, 32 patients altogether had missense mutations in both ATP7B alleles, and eight patients (20 %) were compound heterozygotes possessing the H1069Q mutation on one allele and a severe (i.e., nonsense or frameshift) mutation on the second ATP7B allele.

In the group of neurological ICs and their symptomatic siblings with analyzed ATP7B mutations, the H1069Q mutation reached an allelic frequency of 73.5 %. Twenty-one patients altogether (68 %) had a missense mutation on both ATP7B alleles. Ten individuals (32 %) were compound heterozygotes possessing a missense mutation on one ATP7B allele and a severe mutation on the other allele (Table [3](#Tab3){ref-type="table"}).Table 3Mutation frequencies according to functional severity among index cases (ICs) and their symptomatic siblingsMutationHepatic ICsSiblings of hepatic ICsNeurological ICsSiblings of neurological ICsTotalHQ/HQ121281042HQ/Missense or Missense/Missense441211HQ/Severe or Missense/Severe^a^355518^a^Frameshift and nonsense mutations are considered severe mutations

Aside from H1069Q, the most frequent missense mutations included T997M (c.2930T\>C), T1220M (c.3659C\>T), S653Y (c.1958C\>A), and G988R (c.2962G\>C). Among severe mutations, the T997M (c.2930T\>C), T1220M (c.3659C\>T), S653Y (c.1958C\>A), and G988R (c.2962G\>C) were identified.

Concordance rates and further comparisons were not evaluated because the numbers of patients were too small when patients were assigned to subgroups according to each carrier's mutation status.

Discussion {#Sec9}
==========

Our data revealed an impressive 86 % concordance rate of clinical symptoms between hepatic ICs and their symptomatic siblings at the time of disease onset, and a 66 % concordance rate of clinical symptoms between neurological ICs and their siblings. These results suggest that members of the same family may have very similar phenotypic presentation of WD. These high concordance rates may reflect the influence of inherited genetic similarities (including, but not limited to, the ATP7B mutation) and environmental factors that are shared within the same family and influence affected siblings to a comparable degree and for a comparable period of time. Conversely, less than 100 % concordance may reflect the influence of other non-shared environmental and genetic components, owing to complex individual differences.

There are other autosomal recessive disorders that lack any clear-cut genotype-phenotype correlations, in which other genetic and non-genetic factors are considered to have substantial phenotype-modifying effects (Scriver and Waters [@CR31]; Burke [@CR2]; Rankin et al. [@CR26]). In WD, other genetic factors presumed to influence the phenotype include allele status and the mutations of methyltetrahydrofolate reductase (Gromadzka et al [@CR12]), prion-related protein (PrP) (Merle et al [@CR21]), interleukin-1 receptor antagonist (Gromadzka and Członkowska [@CR9]), or apolipoprotein E genes (Schiefermeier et al [@CR30]; Litwin et al [@CR19]). Individual differences in hepatic copper metabolism, tolerance to copper toxicity, and allelic dominance mechanisms are considered as main determinants of intra-familial diversity in WD (Takeshita et al [@CR34]).

Slightly higher concordance between hepatic ICs and their symptomatic siblings versus neurological ICs and their siblings can be partly explained by the primary principles of copper metabolism, since the liver is the first organ in which copper accumulates and is especially prone to damage caused by copper overload (Linder et al [@CR17]).

Neurological presentation appears to be more complicated and less predictable, given that there are more complex interactions between copper and ceruloplasmin and the central nervous system. First, copper serves as a cofactor and a modulator of enzymes that are crucial for brain homeostasis, such as superoxide dismutase and dopamine hydroxylase. Copper is also centrally involved in iron transport (Cox and Moore [@CR4]) and myelination processes (Prodan et al [@CR25]). Additionally, brain-specific amyloid precursor protein and PrP are copper-binding, copper-dependent proteins that have important roles in neurodegeneration (Multhaup et al [@CR23]; Millhauser [@CR22]). Ceruloplasmin itself is involved in the transport of other metal ions and possesses very strong antioxidant properties, such as ferroxidase activity (Gutteridge [@CR14]). Therefore, reduced ceruloplasmin levels may reflect an increased level of oxidative stress. In conclusion, high intrafamilial concordance rates of clinical and biochemical presentation of WD revealed among siblings shall be a premise for further research regarding the influence of epigenetic, environmental, and other genetic factors.
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